Over the 15 last years, with the introduction of immuno-modulatory drugs (IMiDs), proteasome inhibitors and more recently anti-CD38, SLAM-F7 and BCMA monoclonal antibodies (MoAbs), major advances have revolutionized the treatment of MM. Here, CD38 is linked to Miyoshi myopathy.